Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-08-21 | Reverse | 1:50 |
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
A cancer vaccine candidate currently in Phase II clinical trials. It is designed to stimulate an immune response against various cancers that express Guanylyl Cyclase C, such as colorectal, pancreatic, gastric, and esophageal cancers.
In a highly unusual strategic shift for a biopharmaceutical company, Liminatus Pharma announced in late July 2025 that it was exploring a blockchain-integrated treasury strategy. This culminated in the announcement of plans to launch a subsidiary named “American BNB Strategy” to raise and deploy up to $500 million for investment in BNB, causing a significant surge in stock price and trading volume.
Preclinical biopharmaceutical company Liminatus Pharma announced a significant strategic expansion into the cryptocurrency sector. The company plans to establish a subsidiary, 'American BNB Strategy,' to raise and deploy up to $500 million for long-term investments in BNB coin, the native token of the Binance ecosystem.
FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq's minimum bid price rule.
Overall rating: D+
| PEER | PRICE | |
|---|---|---|
 SABS | $3.14 | COMPARE |
 ATHE | $3.25 | COMPARE |
 EVAX | $3.17 | COMPARE |
 DYAI | $0.44 | COMPARE |
 JSPR | $0.57 | COMPARE |
